Abandoning Eugenics and the QALY.

ICER QALYs denial of care eugenics

Journal

Innovations in pharmacy
ISSN: 2155-0417
Titre abrégé: Innov Pharm
Pays: United States
ID NLM: 101574764

Informations de publication

Date de publication:
2021
Historique:
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

Should decision making in health care, notably in respect of the allocation of resources between individuals and disease states, rest on notions of the burden of disease and denial of care as assessed by societal evaluations or on the extent to which the need of patients and caregivers is fulfilled. The prospect of the denial of health care, for those deemed 'unworthy' has a long history in the eugenics movement. Many have assumed that this 'utilitarian aberration' has long been discredited. Unfortunately, once the question of the allocation of limited health care resources is considered it reasserts itself; manifested in the creation of health state preferences and states worse than death, and application of the cost-per-QALY calculus driving claims for pricing and access. In the US, this focus on cost-per-QALY claims is most closely associated with the Institute for Clinical and Economic Review (ICER) with its regular clinical assessments and modelled imaginary simulations supporting recommendations which, in many if not most cases, give support to the denial of care. The purpose of this commentary is to point to the unfortunate similarities between 'eugenic' decision making and the application of thresholds in burden of illness cost-per-QALY exercises. If we are to finally rid ourselves of a 'eugenic' approach to health care resource allocation, then we must abandon preferences and the QALY calculus.

Identifiants

pubmed: 35601582
doi: 10.24926/iip.v12i3.4291
pmc: PMC9120007
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

© Individual authors.

Références

Innov Pharm. 2020 Nov 12;11(4):
pubmed: 34007644
Innov Pharm. 2021 May 11;12(2):
pubmed: 34345508
Value Health. 2018 Feb;21(2):119-123
pubmed: 29477388
Innov Pharm. 2021 May 25;12(2):
pubmed: 34345518
Soc Sci Med. 2000 Aug;51(3):419-27
pubmed: 10855928
Innov Pharm. 2020 Jul 31;11(3):
pubmed: 34007635
Innov Pharm. 2021 Jun 10;12(3):
pubmed: 35601587

Auteurs

Paul C Langley (PC)

College of Pharmacy, University of Minnesota.

Classifications MeSH